Novavax, Inc. is listed as the second high growth small cap stock that is profitable. Bank of America raised the price target for NVAX to $7 from $6, citing a non-exclusive licensing deal with Pfizer. Bullish options activity was observed on January 21, with call trading at three times normal levels. NVAX is a US biotech company focused on developing innovative vaccines against infectious diseases. Despite the potential of NVAX, there are other AI stocks with greater upside potential and less downside risk. For more information on potential AI investments, refer to the provided link.

Read more at Yahoo Finance: BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets